@phdthesis{Marquardt2023,
  author    = {Marquardt, Andr{\´e}},
  title     = {Machine-Learning-Based Identification of Tumor Entities, Tumor Subgroups, and Therapy Options},
  doi       = {10.25972/OPUS-32954},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-329548},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2023},
  abstract  = {Molecular genetic analyses, such as mutation analyses, are becoming increasingly important in the tumor field, especially in the context of therapy stratification. The identification of the underlying tumor entity is crucial, but can sometimes be difficult, for example in the case of metastases or the so-called Cancer of Unknown Primary (CUP) syndrome. In recent years, methylome and transcriptome utilizing machine learning (ML) approaches have been developed to enable fast and reliable tumor and tumor subtype identification. However, so far only methylome analysis have become widely used in routine diagnostics. The present work addresses the utility of publicly available RNA-sequencing data to determine the underlying tumor entity, possible subgroups, and potential therapy options. Identification of these by ML - in particular random forest (RF) models - was the first task. The results with test accuracies of up to 99\% provided new, previously unknown insights into the trained models and the corresponding entity prediction. Reducing the input data to the top 100 mRNA transcripts resulted in a minimal loss of prediction quality and could potentially enable application in clinical or real-world settings. By introducing the ratios of these top 100 genes to each other as a new database for RF models, a novel method was developed enabling the use of trained RF models on data from other sources. Further analysis of the transcriptomic differences of metastatic samples by visual clustering showed that there were no differences specific for the site of metastasis. Similarly, no distinct clusters were detectable when investigating primary tumors and metastases of cutaneous skin melanoma (SKCM). Subsequently, more than half of the validation datasets had a prediction accuracy of at least 80\%, with many datasets even achieving a prediction accuracy of - or close to - 100\%. To investigate the applicability of the used methods for subgroup identification, the TCGA-KIPAN dataset, consisting of the three major kidney cancer subgroups, was used. The results revealed a new, previously unknown subgroup consisting of all histopathological groups with clinically relevant characteristics, such as significantly different survival. Based on significant differences in gene expression, potential therapeutic options of the identified subgroup could be proposed. Concludingly, in exploring the potential applicability of RNA-sequencing data as a basis for therapy prediction, it was shown that this type of data is suitable to predict entities as well as subgroups with high accuracy. Clinical relevance was also demonstrated for a novel subgroup in renal cell carcinoma. The reduction of the number of genes required for entity prediction to 100 genes, enables panel sequencing and thus demonstrates potential applicability in a real-life setting.},
  subject      = {Maschinelles Lernen},
  language  = {en}
}
@phdthesis{Kaymak2019,
  author    = {Kaymak, Irem},
  title     = {Identification of metabolic liabilities in 3D models of cancer},
  doi       = {10.25972/OPUS-18154},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-181544},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2019},
  abstract  = {Inefficient vascularisation of solid tumours leads to the formation of oxygen and nutrient gradients. In order to mimic this specific feature of the tumour microenvironment, a multicellular tumour spheroid (SPH) culture system was used. These experiments were implemented in p53 isogenic colon cancer cell lines (HCT116 p53 +/+ and HCT116 p53-/-) since Tp53 has important regulatory functions in tumour metabolism. First, the characteristics of the cells cultured as monolayers and as spheroids were investigated by using RNA sequencing and metabolomics to compare gene expression and metabolic features of cells grown in different conditions. This analysis showed that certain features of gene expression found in tumours are also present in spheroids but not in monolayer cultures, including reduced proliferation and induction of hypoxia related genes. Moreover, comparison between the different genotypes revealed that the expression of genes involved in cholesterol homeostasis is induced in p53 deficient cells compared to p53 wild type cells and this difference was only detected in spheroids and tumour samples but not in monolayer cultures. In addition, it was established that loss of p53 leads to the induction of enzymes of the mevalonate pathway via activation of the transcription factor SREBP2, resulting in a metabolic rewiring that supports the generation of ubiquinone (coenzyme Q10). An adequate supply of ubiquinone was essential to support mitochondrial electron transport and pyrimidine biosynthesis in p53 deficient cancer cells under conditions of metabolic stress. Moreover, inhibition of the mevalonate pathway using statins selectively induced oxidative stress and apoptosis in p53 deficient colon cancer cells exposed to oxygen and nutrient deprivation. This was caused by ubiquinone being required for electron transfer by dihydroorotate dehydrogenase, an essential enzyme of the pyrimidine nucleotide biosynthesis pathway. Supplementation with exogenous nucleosides relieved the demand for electron transfer and restored viability of p53 deficient cancer cells under metabolic stress. Moreover, the mevalonate pathway was also essential for the synthesis of ubiquinone for nucleotide biosynthesis to support growth of intestinal tumour organoids. Together, these findings highlight the importance of the mevalonate pathway in cancer cells and provide molecular evidence for an enhanced sensitivity towards the inhibition of mitochondrial electron transfer in tumour-like metabolic environments.},
  subject      = {Tumor},
  language  = {en}
}
@phdthesis{Hoffmann2017,
  author    = {Hoffmann, Helene},
  title     = {Identifying regulators of tumor vascular morphology},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-142348},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2017},
  abstract  = {In contrast to normal vessels, tumor vasculature is structurally and functionally abnormal. Tumor vessels are highly disorganized, tortuous and dilated, with uneven diameter and excessive branching. Consequently, tumor blood flow is chaotic, which leads to hypoxic and acidic regions in tumors. These conditions lower the therapeutic effectiveness and select for cancer cells that are more malignant and metastatic. The therapeutic outcome could be improved by increasing the functionality and density of the tumor vasculature. Tumor angiogenesis also shows parallels to epithelial to mesenchymal transition (EMT), a process enabling metastasis. Metastasis is a multi-step process, during which tumor cells have to invade the surrounding host tissue to reach the circulation and to be transported to distant sites. We hypothesize that the variability in the phenotype of the tumor vasculature is controlled by the differential expression of key transcription factors. Inhibiting these transcription factors might be a promising way for angiogenic intervention and vascular re-engineering. Therefore, we investigated the interdependence of tumor-, stroma- and immune cell-derived angiogenic factors, transcription factors and resulting vessel phenotypes. Additionally, we evaluated whether transcription factors that regulate EMT are promising targets for vascular remodeling. We used formalin fixed paraffin embedded samples from breast cancer patients, classified according to estrogen-, progesterone- and human epidermal growth factor receptor (HER) 2 status. Establishing various techniques (CD34 staining, laser microdissection, RNA isolation and expression profiling) we systematically analyzed tumor and stroma-derived growths factors. In addition, vascular parameters such as microvessel size, area, circularity and density were assessed. Finally the established expression profiles were correlated with the observed vessel phenotype. As the SNAI1 transcriptional repressor is a key regulator of EMT, we examined the effect of vascular knockdown of Snai1 in murine cancer models (E0771, B16-F10 and lewis lung carcinoma). Among individual mammary carcinomas, but not among subtypes, strong differences of vascular parameters were observed. Also, little difference between lobular carcinomas and ductal carcinomas was found. Vessel phenotype of Her2 enriched carcinomas was similar to that of lobular carcinomas. Vessel morphology of luminal A and B and basal-like tumors resembled each other. Expression of angiogenic factors was variable across subtypes. We discovered an inverse correlation of PDGF-B and VEGF-A with vessel area in luminal A tumors. In these tumors expression of IL12A, an inhibitor of angiogenesis, was also correlated with vessel size. Treatment of endothelial cells with growth factors revealed an increased expression of transcription factors involved in the regulation of EMT. Knockdown of Snai1 in endothelial cells of mice increased tumor growth and decreased hypoxia in the E0771 and the B16-F10 models. In the lewis lung carcinomas, tumor vascularity and biodistribution of doxorubicin were improved. Here, doxorubicin treatment in combination with the endothelial cell-specific knockdown did slow tumor growth. This shows that SNAI1 is important for a tumor's vascularization, with the significance of its role depending on the tumor model. The methods established in this work open the way for the analysis of the expression of key transcription factors in vessels of formalin fixed paraffin embedded tumors. This research enables us to find novel targets for vascular intervention and to eventually design novel targeted drugs to inhibit these targets.},
  subject      = {Antiangiogenese},
  language  = {en}
}
@phdthesis{Schmitt2013,
  author    = {Schmitt, Peter},
  title     = {MR imaging of tumors: Approaches for functional and fast morphological characterization},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-135967},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2013},
  abstract  = {The subject of this work was to develop, implement, optimize and apply methods for quantitative MR imaging of tumors. In the context of functional and physiological characterization, this implied transferring techniques established in tumor model research to human subjects and assessing their feasibility for use in patients. In the context of the morphologic assessment and parameter imaging of tumors, novel concepts and techniques were developed, which facilitated the simultaneous quantification of multiple MR parameters, the generation of "synthetic" MR images with various contrasts, and the fast single-shot acquisition of purely T2-weighted images.},
  subject      = {Kernspintomografie},
  language  = {en}
}
@phdthesis{Huang2013,
  author    = {Huang, Ting},
  title     = {Vaccinia Virus-mediated Therapy of Solid Tumor Xenografts: Intra-tumoral Delivery of Therapeutic Antibodies},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-91327},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2013},
  abstract  = {Over the past 30 years, much effort and financial support have been invested in the fight against cancer, yet cancer still represents the leading cause of death in the world. Conventional therapies for treatment of cancer are predominantly directed against tumor cells. Recently however, new treatments options have paid more attention to exploiting the advantage of targeting the tumor stroma instead. Vaccinia virus (VACV) has played an important role in human medicine since the 18th century as a vaccination against smallpox. In our laboratory, the recombinant, replication-competent vaccinia virus, GLV-1h68, was shown to enter, colonize and destroy cancer cells both in cell culture, and in vivo, in xenograft models (Zhang, Yu et al. 2007). In addition, combined therapy of GLV-1h68 and anti-VEGF immunotherapy significantly enhanced antitumor therapy in vivo (Frentzen, Yu et al. 2009). In this study, we constructed several new recombinant VACVs carrying genes encoding different antibodies against fibroblast activation protein (FAP) in stroma (GLV-1h282), nanobody against the extracellular domain of epidermal growth factor receptor (EGFR, GLV-1h442) or antibodies targeting both vascular endothelial growth factor (VEGF) and EGFR (GLV-1h444) or targeting both VEGF and FAP (GLV-1h446). The expression of the recombinant proteins was first verified using protein analytical methods, SDS-gel electrophoresis, Western blot analysis, immunoprecipitation (IP) assays and ELISA assays. The proteins were detected after infection of the cells with the different VACVs and the recombinant proteins purified by affinity adsorption. The purified antibodies were shown to specifically bind to their respective antigens. Secondly, the infection and replication capability of all the virus strains was analyzed in cell culture using several human tumor cell lines (A549, FaDu or DU145), revealing that all the new recombinant VACVs were able to infect cancer cells with comparable efficiency to the parental viruses from which they were derived. Thirdly, the antitumor efficacy of the new recombinant VACVs was evaluated in vivo using several human cancer xenograft models in mice. In A549 and DU145 xenografts, the new recombinant VACVs exhibited an enhanced therapeutic efficacy compared to GLV-1h68 with no change in toxicity in mice. In the FaDu xenograft, treatment with GLV-1h282 (anti-FAP) significantly slowed down the speed of tumor growth compared to GLV-1h68. Additionally, treatment with the recombinant VACVs expressed the various antibodies achieved comparable or superior therapeutic effects compared to treatment with a combination of GLV-1h68 and the commercial therapeutic antibodies, Avastin, Erbitux or both. Next, the virus distribution in tumors and organs of treated mice was evaluated. For most of the viruses, the virus titer in tumors was not signficantly diffferent than GLV-1h68. However, for animals treated with GLV-1h282, the virus titer in tumors was significantly higher than with GLV-1h68. This may be the reason for enhanced antitumor efficacy of GLV-1h282 in vivo. Lastly, the underlying mechanisms of therapeutic antibody-enhanced antitumor effects were investigated by immunohistochemistry. Blood vessels density and cell proliferation in tumors were suppressed after treatment with the antibody-encoded VACVs. The results indicated that the suppression of angiogenesis or cell proliferation in tumors may cause the observed therapeutic effect. In conclusion, the results of the studies presented here support the hypothesis that the treatment of solid tumors with a combination of oncolytic virotherapy and immunotherapy has an additive effect over each treatment alone. Moreover, expression of the immunotherapeutic antibody by the oncolytic VACV locally in the tumor enhances the antitumor effect over systemic treatment with the same antibody. Combined, these results indicate that therapy with oncolytic VACVs expressing-therapeutic antibodies may be a promising approach for the treatment of cancer.},
  subject      = {Vaccinia-Virus},
  language  = {en}
}
@phdthesis{Nube2013,
  author    = {Nube, Jacqueline Sui Lin},
  title     = {Comparative Analysis of Vaccinia Virus-Encoded Markers Reflecting Actual Viral Titres in Oncolytic Virotherapy},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-85689},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2013},
  abstract  = {Using viruses to treat cancer is a novel approach to an age-old disease. Oncolytic viruses are native or recombinant viruses that have the innate or enhanced capability to infect tumour cells, replicate within the tumour microenvironment and subsequently lyse those cells. One representative, the vaccinia virus (VACV), belongs to the orthopoxvirus genus of the Poxviridae family. GLV-1h68, a recombinant and attenuated vaccinia virus devel- oped by the Genelux Corporation, is a member of this family currently being tested in various phase I/II clinical trials under the name GL-ONC1. It has been shown to specif- ically replicate in tumour cells while sparing healthy tissue and to metabolise prodrug at or transport immunological payloads to the site of affliction. Since imaging modalities offer little insight into viral replication deep within the body, and because oncolytic virotherapy is dependent on replication within the target tissue, the need for a monitoring system is evident. Pharmacokinetic analysis of this oncolytic agent was to give insight into the dynamics present in tumours during treatment. This, in turn, would give clinicians the opportunity to monitor the efficacy as early as possible after the onset of treatment, to observe treatment progression and possibly to gauge prognosis, without resorting to invasive procedures, e.g. biopsies. A criteria for viable biomarkers was that it had to be directly dependent on viral replica- tion. Ideally, a marker for treatment efficacy would be specific to the treatment modality, not necessarily the treatment type. Such a marker would be highly detectable (high sen- sitivity), specific for the treatment (high specificity), and present in an easily obtained specimen (blood). Taking this into consideration, the biomarkers were chosen for their potential to be indicators of viral replication. Thus, the biomarkers analysed in this thesis are: the native proteins expressed by the viral genes A27L and B5R, the virally encoded recombinant proteins β-galactosidase, β-glucuronidase, green fluorescent protein (GFP), carboxypeptidase G2 (CPG2) and carcinoembryonic antigen (CEA). Each marker is under the control of one of five different promoters present. All recombinant viruses used in this thesis express A27L, B5R, GFP and β-glucuronidase and all are derived from the parental virus GLV-1h68. In addition to these markers, GLV-1h68 expresses β-galactosidase; GLV-1h181 expresses CPG2. [...]},
  subject      = {Onkolyse},
  language  = {en}
}
@phdthesis{Geissinger2010,
  author    = {Geissinger, Ulrike},
  title     = {Vaccinia Virus-mediated MR Imaging of Tumors in Mice: Overexpression of Iron-binding Proteins in Colonized Xenografts},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-48099},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2010},
  abstract  = {Vaccinia virus plays an important role in human medicine and molecular biology ever since the 18th century after E. Jenner discovered its value as a vaccination virus against smallpox. After the successful eradication of smallpox, vaccinia virus, apart from its use as a vaccine carrier, is today mainly used as a viral vector in molecular biology and increasingly in cancer therapy. The capability to specifically target and destroy cancer cells makes it a perfect agent for oncolytic virotherapy. Furthermore, the virus can easily be modified by inserting genes encoding therapeutic or diagnostic proteins to be expressed within the tumor. The emphasis in this study was the diagnosis of tumors using different vaccinia virus strains. Viruses with metal-accumulating capabilities for tumor detection via MRI technology were generated and tested for their usefulness in cell culture and in vivo. The virus strains GLV-1h131, GLV-1h132, and GLV-1h133 carry the gene encoding the two subunits of the iron storage protein ferritin under the control of three different promoters. GLV-1h110, GLV-1h111, and GLV-1h112 encode the bacterial iron storage protein bacterioferritin, whereas GLV-1h113 encodes the codon-optimized version of bacterioferritin for more efficient expression in human cells. GLV-1h22 contains the transferrin receptor gene, which plays an important role in iron uptake, and GLV-1h114 and GLV-1h115 contain the murine transferrin receptor gene. For possibly better iron uptake the virus strains GLV-1h154, GLV-1h155, GLV-1h156, and GLV-1h157 were generated, each with a version of a ferritin gene and a transferrin receptor gene. GLV-1h154 carries the genes that encode bacterioferritin and human transferrin receptor, GLV-1h155 the human ferritin H-chain gene and the human transferrin receptor gene. GLV-1h156 and GLV-1h157 infected cells both express the mouse transferrin receptor and bacterioferritin or human ferritin H-chain, respectively. The virus strains GLV-1h186 and GLV-1h187 were generated to contain a mutated form of the ferritin light chain, which was shown to result in iron overload and the wildtype light chain gene, respectively. The gene encoding the Divalent Metal Transporter 1, which is a major protein in the uptake of iron, was inserted in the virus strain GLV-1h102. The virus strain GLV-1h184 contains the magA gene of the magnetotactic bacterium Magnetospirillum magnetotacticum, which produces magnetic nanoparticles for orientation in the earth's magnetic field. Initially the infection and replication capability of all the virus strains were analyzed and compared to that of the parental virus strain GLV-1h68, revealing that all the viruses were able to infect cells of the human cancer cell lines A549 and GI-101A. All constructs exhibited a course of infection comparable to that of GLV-1h68. Next, to investigate the expression of the foreign proteins in GI-101A and A549 cells with protein analytical methods, SDS-gelelectrophoresis, Western blots and ELISAs were performed. The proteins, which were expressed under the control of the strong promoters, could be detected using these methods. To be able to successfully detect the protein expression of MagA and DMT1, which were expressed under the control of the weak promoter, the more sensitive method RT-PCR was used to at least confirm the transcription of the inserted genes. The determination of the iron content in infected GI-101A and A549 cells showed that infection with all used virus strains led to iron accumulation in comparison to uninfected cells, even infection with the parental virus strain GLV-1h68. The synthetic phytochelatin EC20 was also shown to enhance the accumulation of different heavy metals in bacterial cultures. In vivo experiments with A549 tumor-bearing athymic nude mice revealed that 24 days post infection virus particles were found mainly in the tumor. The virus-mediated expression of recombinant proteins in the tumors was detected successfully by Western blot. Iron accumulation in tumor lysates was investigated by using the ferrozine assay and led to the result that GLV-1h68-infected tumors had the highest iron content. Histological stainings confirmed the finding that iron accumulation was not a direct result of the insertion of genes encoding iron-accumulating proteins in the virus genome. Furthermore virus-injected tumorous mice were analyzed using MRI technology. Two different measurements were performed, the first scan being done with a seven Tesla small animal scanner seven days post infection whereas the second scan was performed using a three Tesla human scanner 21 days after virus injection. Tumors of mice injected with the virus strains GLV-1h113 and GLV-1h184 were shown to exhibit shortened T2 and T2* relaxation times, which indicates enhanced iron accumulation. In conclusion, the experiments in this study suggest that the bacterioferritin-encoding virus strain GLV-1h113 and the magA-encoding virus strain GLV-1h184 are promising candidates to be used for cancer imaging after further analyzation and optimization.},
  subject      = {Vaccinia-Virus},
  language  = {en}
}
@phdthesis{Worschech2010,
  author    = {Worschech, Andrea},
  title     = {Oncolytic Therapy with Vaccinia Virus GLV-1h68 - Comparative Microarray Analysis of Infected Xenografts and Human Tumor Cell Lines -},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-45338},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2010},
  abstract  = {Aim of this thesis was to study the contribution of the hosts immune system during tumor regression. A wild-type rejection model was studied in which tumor regression is mediated through an adaptive, T cell host response (Research article 1). Additionally, the relationship between VACV infection and cancer rejection was assessed by applying organism-specific microarray platforms to infected and non-infected xenografts. It could be shown that tumor rejection in this nude mouse model was orchestrated solely by the hosts innate immune system without help of the adaptive immunity. In a third study the inflammatory baseline status of 75 human cancer cell lines was tested in vitro which was correlated with the susceptibility to VACV and Adenovirus 5 (Ad5) replication of the respective cell line (Manuscript for Research article 3). Although xenografts by themselves lack the ability to signal danger and do not provide sufficient proinflammatory signals to induce acute inflammation, the presence of viral replication in the oncolytic xenograft model provides the "tissue-specific trigger" that activates the immune response and in concordance with the hypothesis, the ICR is activated when chronic inflammation is switched into an acute one. Thus, in conditions in which a switch from a chronic to an acute inflammatory process can be induced by other factors like the immune-stimulation induced by the presence of a virus in the target tissue, adaptive immune responses may not be necessary and immune-mediated rejection can occur without the assistance of T or B cells. However, in the regression study using neu expressing MMC in absence of a stimulus such as a virus and infected cancer cells thereafter, adaptive immunity is needed to provoke the switch into an acute inflammation and initiate tissue rejection. Taken together, this work is supportive of the hypothesis that the mechanisms prompting TSD differ among immune pathologies but the effect phase converges and central molecules can be detected over and over every time TSD occurs. It could be shown that in presence of a trigger such as infection with VACV and functional danger signaling pathways of the infected tumor cells, innate immunity is sufficient to orchestrate rejection of manifested tumors.},
  subject      = {Tumorimmunologie},
  language  = {en}
}
@phdthesis{Engelmann2008,
  author    = {Engelmann, Julia Cath{\´e}rine},
  title     = {DNA microarrays: applications and novel approaches for analysis and interpretation},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-29747},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2008},
  abstract  = {In der vorliegenden Dissertation wird die Entwicklung eines phylogenetischen DNA Microarrays, die Analyse von mehreren Microarray-Genexpressionsdatens{\"a}tzen und neue Ans{\"a}tze f{\"u}r die Datenanalyse und Interpretation der Ergebnisse vorgestellt. Die Entwicklung und Analyse der Daten eines phylogenetischen DNA Microarrays wird in der ersten Publikation dargestellt. Ich konnte zeigen, dass die Spezies-Detektion mit phylogenetischen Microarrays durch die Datenanalyse mit einem linearen Regressionsansatz signifikant verbessert werden kann. Standard-Methoden haben bislang nur Signalintensit{\"a}ten betrachtet und eine Spezies als an- oder abwesend bezeichnet, wenn die Signalintensit{\"a}t ihres Messpunktes oberhalb eines willk{\"u}rlich gesetzten Schwellenwertes lag. Dieses Verfahren ist allerdings aufgrund von Kreuz-Hybridisierungen nicht auf sehr nah verwandte Spezies mit hoher Sequenzidentit{\"a}t anwendbar. Durch die Modellierung des Hybridisierungs und Kreuz-Hybridisierungsverhaltens mit einem linearen Regressionsmodell konnte ich zeigen, dass Spezies mit einer Sequenz{\"a}hnlichkeit von 97\% im Markergen immer noch unterschieden werden k{\"o}nnen. Ein weiterer Vorteil der Modellierung ist, dass auch Mischungen verschiedener Spezies zuverl{\"a}ssig vorhergesagt werden k{\"o}nnen. Theoretisch sind auch quantitative Vorhersagen mit diesem Modell m{\"o}glich. Um die großen Datenmengen, die in {\"o}ffentlichen Microarray-Datenbanken abgelegt sind besser nutzen zu k{\"o}nnen, bieten sich Meta-Analysen an. In der zweiten Publikation wird eine explorative Meta-Analyse auf Arabidopsis thaliana-Datens{\"a}tzen vorgestellt. Mit der Analyse verschiedener Datens{\"a}tze, die den Einfluss von Pflanzenhormonen, Pathogenen oder verschiedenen Mutationen auf die Genexpression untersucht haben, konnten die Datens{\"a}tze anhand ihrer Genexpressionsprofile in drei große Gruppen eingeordnet werden: Experimente mit Indol-3-Essigs{\"a}ure (IAA), mit Pathogenen und andere Experimente. Gene, die charakteristisch f{\"u}r die Gruppe der IAA-Datens{\"a}tze beziehungsweise f{\"u}r die Gruppe der Pathogen-Datens{\"a}tze sind, wurden n{\"a}her betrachtet. Diese Gene hatten Funktionen, die bereits mit Pathogenbefall bzw. dem Einfluss von IAA in Verbindung gebracht wurden. Außerdem wurden Hypothesen {\"u}ber die Funktionen von bislang nicht annotierten Genen aufgestellt. In dieser Arbeit werden auch Prim{\"a}ranalysen von einzelnen Arabidopsis thaliana Genexpressions-Datens{\"a}tzen vorgestellt. In der dritten Publikation wird ein Experiment beschrieben, das durchgef{\"u}hrt wurde um herauszufinden ob Mikrowellen-Strahlung einen Einfluss auf die Genexpression einer Zellkultur hat. Dazu wurden explorative Analysemethoden angewendet. Es wurden geringe aber signifikante Ver{\"a}nderungen in einer sehr kleinen Anzahl von Genen beobachtet, die experimentell best{\"a}tigt werden konnten. Die Funktionen der regulierten Gene und eine Meta-Analyse mit {\"o}ffentlich zug{\"a}nglichen Datens{\"a}tzen einer Datenbank deuten darauf hin, dass die pflanzliche Zellkultur die Strahlung als eine Art Energiequelle {\"a}hnlich dem Licht wahrnimmt. Des weiteren wird in der vierten Publikation die funktionelle Analyse eines Arabidopsis thaliana Genexpressionsdatensatzes beschrieben. Die Analyse der Genexpressions eines pflanzlichen Tumores zeigte, dass er seinen Stoffwechsel von aerob und auxotroph auf anaerob und heterotroph umstellt. Gene der Photosynthese werden im Tumorgewebe reprimiert, Gene des Aminos{\"a}ure- und Fettstoffwechsels, der Zellwand und Transportkan{\"a}le werden so reguliert, dass Wachstum und Entwicklung des Tumors gef{\"o}rdert werden. In der f{\"u}nften Publikation in dieser Arbeit wird GEPAT (Genome Expression Pathway Analysis Tool) beschrieben. Es besteht aus einer Internet- Anwendung und einer Datenbank, die das einfache Hochladen von Datens{\"a}tzen in die Datenbank und viele M{\"o}glichkeiten der Datenanalyse und die Integration anderer Datentypen erlaubt. In den folgenden zwei Publikationen (Publikation 6 und Publikation 7) wird GEPAT auf humane Microarray-Datens{\"a}tze angewendet um Genexpressionsdaten mit weiteren Datentypen zu verkn{\"u}pfen. Genexpressionsdaten und Daten aus vergleichender Genom-Hybridisierung (CGH) von prim{\"a}ren Tumoren von 71 Mantel-Zell-Lymphom (MCL) Patienten erm{\"o}glichte die Ermittlung eines Pr{\"a}diktors, der die Vorhersage der {\"U}berlebensdauer von Patienten gegen{\"u}ber herk{\"o}mmlichen Methoden verbessert. Die Analyse der CGH Daten zeigte, dass auch diese f{\"u}r die Vorhersage der {\"U}berlebensdauer geeignet sind. F{\"u}r den Datensatz von Patienten mit großzellig diffusem B-Zell-Lymphom DLBCL konnte aus den Genexpressionsdaten ebenfalls ein neuer Pr{\"a}diktor vorgeschlagen werden. Mit den zwischen lang und kurz {\"u}berlebenden Patienten differentiell exprimierten Genen der MCL Patienten und mit den Genen, die zwischen den beiden Untergruppen von DLBCL reguliert sind, wurden Interaktionsnetzwerke gebildet. Diese zeigen, dass bei beiden Krebstypen Gene des Zellzyklus und der Proliferation zwischen Patienten mit kurzer und langer {\"U}berlebensdauer unterschiedlich reguliert sind.},
  subject      = {Microarray},
  language  = {en}
}
@incollection{AltschmiedSchartl1994,
  author    = {Altschmied, Joachim and Schartl, Manfred},
  title     = {Genetics and molecular biology of tumour formation in Xiphophorus},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-69752},
  publisher      = {Universit{\"a}t W{\"u}rzburg},
  year      = {1994},
  abstract  = {No abstract available.},
  subject      = {Schwertk{\"a}rpfling},
  language  = {en}
}
@article{WinklerWittbrodtLammersetal.1994,
  author    = {Winkler, Christoph and Wittbrodt, Joachim and Lammers, Reiner and Ullrich, Axel and Schartl, Manfred},
  title     = {Ligand-dependent tumor induction in medakafish embryos by a Xmrk receptor tyrosine kinase transgene},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-87107},
  year      = {1994},
  abstract  = {Xmrk encodes a subclass 1 receptor tyrosine kinase (RTK) which has been cloned from the melanomainducing locus Tu of the poeciliid fish Xiphophorus. To demonstrate a high oncogenic potential in vivo we transferred the gene into early embryos of the closely related medakafish. Ectopic expression of the Xmrk oncogene under the control of a strong, constitutive promoter (CMVTk) led to the induction of embryonic tumors with high incidence, after short latency periods, and with a specific pattern of affected tissues. We demonstrate ligand-dependent transformation in vivo using a chimeric receptor consisting of the extracellular and transmembrane domains of the human EGF receptor (HER) and the cytoplasmatic domain of Xmrk. Expression of the chimeric receptor alone does not lead to ldnase activation or induction of tumors. Coexpression of the chimera with its corresponding ligand, human transforming growth factor alpha (bTGF(X), however, results in the activation of the chimeric RTK. In injected fish embryos the induction of the neoplastic growth is observed with similar incidence and tissue distribution as in embryos carrying the native Xmrk oncogene suggesting that the ligand as well as factors downstream of tbe RTK are required for tumor formation. In this study we show single-step induction of tumors by ectopic expression of RTKs in vivo substantiating tbe significance of autocrine stimulation in RTK induced tumors in vertebrales.},
  subject      = {Japank{\"a}rpfling},
  language  = {en}
}
@incollection{AdamSchartlAndexingeretal.1991,
  author    = {Adam, D. and Schartl, A. and Andexinger, S. and H{\"o}lter, S. and Wilde, B. and Schartl, Manfred},
  title     = {Genetic factors in tumour formation: The melanoma-inducing gene of Xiphophorus},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-86388},
  publisher      = {Universit{\"a}t W{\"u}rzburg},
  year      = {1991},
  abstract  = {No abstract available.},
  subject      = {Humangenetik},
  language  = {en}
}
@inproceedings{AndersSchollSchartl1981,
  author    = {Anders, F. and Scholl, E. and Schartl, Manfred},
  title     = {Environmental and hereditary factors in the causation of neoplasia, based on studies of the Xiphophorus fish melanoma system},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-86402},
  year      = {1981},
  abstract  = {Neoplasia in Xiphophorus can be classified into: a) a Jarge group triggered by carcinogens; b) a large group triggered by promoters; and c) a small group that develops "spontaneously" according to Mendelian Jaw. The process leading to susceptibility for neoplasia is represented by the disintegration of gene systems that normally protect the fish from neoplasia. Interpopulational arid interracial hybridization is the most effective process that Ieads to disintegration of the protective gene systems. Environmental factors may complete disintegration in somatic cells and thus may trigger neoplasia. The applications of the findings on Xiphophorus to humans are discussed.},
  subject      = {Schwertk{\"a}rpfling},
  language  = {en}
}